Longitudinal and Seasonal Trends in Reimbursed and Non‐Reimbursed Methylphenidate Dispense and Its Most Common Alternatives in Belgium
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70380 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Natan Van Wichelen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Toxicological Centre, University of Antwerp, Antwerp, Belgium. Hauptthemen laut MEDLINE: Methylphenidate, Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Seasons. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Purpose
The dispense of methylphenidate (MPH) for attention‐deficit hyperactivity disorder (ADHD) treatment often raises concerns about overdiagnosis, over‐, mis‐, and abuse. However, in‐depth temporal analyses on dispensing and reimbursement data are lacking in Belgium and globally.
Methods
Longitudinal trends in the dispensing of MPH and its alternatives, including atomoxetine (ATO), modafinil (MOD), and guanfacine (GUA), were analyzed from 2011 to 2022 in Belgium using data from IFSTAT and IQVIA databanks. The dataset uniquely separates MPH and MOD into reimbursed and non‐reimbursed categories across age groups (6–17 and > 17 years). These trends were further examined in the context of international literature to provide a comprehensive framework for comparison.
Results
MPH is the most prescribed ADHD medication. Over the 12‐year study period, all included drugs showed an increasing trend. For MPH and MOD, this rise is driven by non‐reimbursed dispensing, while reimbursed dispensing remained stable. During summer months, a seasonal drop in MPH dispensing for the 6–17Y age group suggests an annual ’MPH drug holiday’ to evaluate the necessity of continued use. While comprehensive pharmacovigilance is currently limited by insufficient demographic data and specific prescription indications, addressing these gaps presents an opportunity to better understand the underlying causes of observed dispensing trends.
Conclusion
Differentiating between reimbursed and non‐reimbursed dispensing is crucial to accurately describe the increasing use of this group of ADHD medication. More granular data is needed to assess whether changes to prescribing practices are necessary and to inform future development of guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Toxicological Centre, University of Antwerp, Antwerp, Belgium.
- Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium.
ORCID-Profile: Natan Van Wichelen
Förderung
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Van Wichelen, N., Boogaerts, T., Raeime, A., Ferreira, L. S., Gys, C., Covaci, A., van Nuijs, A. L. N., & De Loof, H. (2026). Longitudinal and Seasonal Trends in Reimbursed and Non‐Reimbursed Methylphenidate Dispense and Its Most Common Alternatives in Belgium. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70380
Vancouver
Van Wichelen N, Boogaerts T, Raeime A, Ferreira LS, Gys C, Covaci A, et al. Longitudinal and Seasonal Trends in Reimbursed and Non‐Reimbursed Methylphenidate Dispense and Its Most Common Alternatives in Belgium. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70380
BibTeX
@article{VanWichelen2026,
author = {Van Wichelen, Natan and Boogaerts, Tim and Raeime, Arzo and Ferreira, Laurinda Sa and Gys, Celine and Covaci, Adrian and van Nuijs, Alexander L N and De Loof, Hans},
title = {Longitudinal and Seasonal Trends in Reimbursed and Non‐Reimbursed Methylphenidate Dispense and Its Most Common Alternatives in Belgium},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70380}
}
EUVIMED